Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KINETA, INC./DEPTI · Entity 77778 | See Remarks | April 03, 2017 | April 05, 2017 |
| Kalaris Therapeutics, Inc.KLRS · Entity 6805 | Chief Accounting Officer | March 19, 2026 | March 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KINETA, INC./DE
Report date April 03, 2017 · Filed April 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.56 · Expires 2027-04-03 | Direct | 21,100 |
Reported balance
After 2017-04-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-04-03 · Grant · Acquired 21,100 · Balance 21,100 F1: These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on March 8, 2018, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on March 8, 2021, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on March 8, 2018, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on March 8, 2021, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities.
Kalaris Therapeutics, Inc.
Report date March 19, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-03-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-20 · Sale · Disposed 1,915 · Balance 0 F1: Due to an administrative error, the Reporting Person filed a Form 4 on March 27, 2025 reporting beneficial ownership of 1,925 shares, when in fact the amount of securities beneficially owned was 1,915. The number of shares beneficially owned by the Reporting Person following the transaction reported herein has been updated accordingly. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.81 · Expires 2036-03-18 | Direct | 60,800 |
Reported balance
After 2026-03-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-19 · Grant · Acquired 60,800 · Balance 60,800 F2: The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Due to an administrative error, the Reporting Person filed a Form 4 on March 27, 2025 reporting beneficial ownership of 1,925 shares, when in fact the amount of securities beneficially owned was 1,915. The number of shares beneficially owned by the Reporting Person following the transaction reported herein has been updated accordingly.
F2: The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2026 Filed Mar 23, 2026 20:05 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | SaleCommon Stock | 1,915 | $6.72 | $12,868.80 |
DisclosureSEC source: 0001193125-26-119707 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · balance_after: Due to an administrative error, the Reporting Person filed a Form 4 on March 27, 2025 reporting beneficial ownership of 1,925 shares, when in fact the amount of securities beneficially owned was 1,915. The number of shares beneficially owned by the Reporting Person following the transaction reported herein has been updated accordingly. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 20:05 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 60,800 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001193125-26-119707 · ownership.xml · derivative · entry 2 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,800 Underlying: Common Stock · 60,800 shares Expires 2036-03-18 F2 · derivative.exercise_date: The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 21:27 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 50,262 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0000950170-25-053382 · ownership.xml · derivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,262 Underlying: Common Stock · 50,262 shares Expires 2035-04-09 F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service. Read SEC document |
| March 26, 2025 Filed Mar 27, 2025 23:19 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | SaleCommon Stock | 907 | $8.97 | $8,135.16 |
DisclosureSEC source: 0000950170-25-046263 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,925 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.70 to $9.60. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2). Read SEC document |
| February 21, 2025 Filed Feb 24, 2025 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 96 | $10.08 | $967.28 |
DisclosureSEC source: 0000950170-25-025633 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,832 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 4 | $9.94 | $39.76 |
DisclosureSEC source: 0000950170-25-009204 · ownership.xml · nonDerivative · entry 2 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,928 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.81 to $10.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 32 | $9.45 | $302.52 |
DisclosureSEC source: 0000950170-25-009204 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,932 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.81 to $9.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 332 | $0.44 | $146.11 |
DisclosureSEC source: 0000950170-25-004833 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,174 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.462. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 554 | $0.55 | $303.87 |
DisclosureSEC source: 0000950170-24-129263 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,506 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 05, 2024 Filed Nov 6, 2024 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,655 | $0.86 | $1,431.41 |
DisclosureSEC source: 0000950170-24-122334 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,060 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.856 to $0.9151. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 22, 2024 Filed Oct 23, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 486 | $0.77 | $373.15 |
DisclosureSEC source: 0000950170-24-116646 · ownership.xml · nonDerivative · entry 2 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,715 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.76 to $0.7709. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 479 | $0.78 | $373.14 |
DisclosureSEC source: 0000950170-24-116646 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,201 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7544 to $0.7964. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 301 | $0.81 | $245.25 |
DisclosureSEC source: 0000950170-24-112911 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,680 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 544 | $0.76 | $413.17 |
DisclosureSEC source: 0000950170-24-099104 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,981 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7373 to $0.7736. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,692 | $0.73 | $1,243.28 |
DisclosureSEC source: 0000950170-24-092806 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,525 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.73 to $0.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 20:28 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 481 | $0.74 | $355.56 |
DisclosureSEC source: 0000950170-24-085670 · ownership.xml · nonDerivative · entry 2 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,217 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7330 to $0.7534. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 20:28 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 479 | $0.75 | $359.30 |
DisclosureSEC source: 0000950170-24-085670 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,698 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7343 to $0.7925. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 20:12 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 304 | $0.72 | $218.88 |
DisclosureSEC source: 0000950170-24-081515 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,177 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| May 17, 2024 Filed May 21, 2024 20:35 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 541 | $0.75 | $405.37 |
DisclosureSEC source: 0000950170-24-062983 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,481 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.74 to $0.7615. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 03, 2024 Filed May 7, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,597 | $0.80 | $1,271.21 |
DisclosureSEC source: 0000950170-24-054510 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,022 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7801 to $0.8098. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 22, 2024 Filed Apr 23, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 480 | $0.75 | $360.00 |
DisclosureSEC source: 0000950170-24-046906 · ownership.xml · nonDerivative · entry 2 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,619 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 473 | $0.75 | $355.03 |
DisclosureSEC source: 0000950170-24-046906 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,099 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7460 to $0.7562. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 281 | $0.77 | $216.93 |
DisclosureSEC source: 0000950170-24-041811 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,572 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7513 to $0.7801. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 494 | $0.70 | $343.43 |
DisclosureSEC source: 0000950170-24-018780 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,853 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6832 to $0.7150. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:01 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 11,150 | $0.67 | $7,493.92 |
DisclosureSEC source: 0000950170-24-013491 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,347 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.672 to $0.6721. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 21:39 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 5,792 | $0.67 | $3,880.64 |
DisclosureSEC source: 0000950170-24-011770 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,497 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.66 to $0.6914. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 901 | $0.67 | $604.39 |
DisclosureSEC source: 0000950170-24-007404 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,289 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6683 to $0.6797. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 310 | $0.64 | $198.09 |
DisclosureSEC source: 0000950170-24-002934 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,190 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| December 27, 2023 Filed Jan 3, 2024 00:36 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 28,335 | $0.74 | $20,837.56 |
DisclosureSEC source: 0000950170-24-000428 · ownership.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,500 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7228 to $0.7452. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 22:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 403 | $1.63 | $657.33 |
DisclosureSEC source: 0001209191-23-056320 · doc4.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,835 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.61 to $1.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 20, 2023 Filed Oct 23, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 357 | $1.54 | $550.14 |
DisclosureSEC source: 0001209191-23-053347 · doc4.xml · nonDerivative · entry 2 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,238 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.53 to $1.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 19, 2023 Filed Oct 23, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 358 | $1.58 | $565.64 |
DisclosureSEC source: 0001209191-23-053347 · doc4.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,595 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 222 | $1.98 | $438.74 |
DisclosureSEC source: 0001209191-23-052227 · doc4.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,953 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.95 to $2.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,653 | $2.50 | $4,125.06 |
DisclosureSEC source: 0001209191-23-046731 · doc4.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,175 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.45 to $2.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 342 | $3.35 | $1,144.81 |
DisclosureSEC source: 0001209191-23-043120 · doc4.xml · nonDerivative · entry 2 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,828 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.26 to $3.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 342 | $3.56 | $1,218.03 |
DisclosureSEC source: 0001209191-23-043120 · doc4.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,170 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.53 to $3.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 5,045 | $5.64 | $28,452.79 |
DisclosureSEC source: 0001209191-23-036796 · doc4.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,512 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.56 to $5.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 20, 2023 Filed Apr 21, 2023 20:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 349 | $3.63 | $1,265.30 |
DisclosureSEC source: 0001209191-23-025116 · doc4.xml · nonDerivative · entry 2 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,557 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.62 to $3.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 20:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 348 | $3.71 | $1,290.63 |
DisclosureSEC source: 0001209191-23-025116 · doc4.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,906 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.64 to $3.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 113,750 | $0.00 Strike: $6.65 | $0.00 |
DisclosureSEC source: 0001209191-23-006989 · doc4.xml · derivative · entry 2 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,708 Underlying: Common Stock · 113,750 shares Expires 2033-02-02 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 61,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006989 · doc4.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,254 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 00:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 338 | $5.14 | $1,738.60 |
DisclosureSEC source: 0001209191-23-004500 · doc4.xml · nonDerivative · entry 2 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,004 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.05 to $5.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 19, 2023 Filed Jan 24, 2023 00:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,557 | $5.08 | $7,905.98 |
DisclosureSEC source: 0001209191-23-004500 · doc4.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,342 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.94 to $5.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 22:06 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 18,011 | $8.18 | $147,257.94 |
DisclosureSEC source: 0000899243-22-035701 · doc4.xml · nonDerivative · entry 2 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,899 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.49. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 22:06 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 5,989 | $8.00 | $47,924.58 |
DisclosureSEC source: 0000899243-22-035701 · doc4.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,910 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.015. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 24, 2022 Filed Oct 24, 2022 22:25 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,000 | $8.13 | $16,269.00 |
DisclosureSEC source: 0000899243-22-034057 · doc4.xml · nonDerivative · entry 3 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,899 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 21, 2022 Filed Oct 24, 2022 22:25 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 11,334 | $8.45 | $95,799.50 |
DisclosureSEC source: 0000899243-22-034057 · doc4.xml · nonDerivative · entry 2 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,899 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.27 to $8.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 20, 2022 Filed Oct 26, 2022 20:15 UTC Amendment | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 345 | $9.36 | $3,229.44 |
DisclosureSEC source: 0000899243-22-034263 · doc4a.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,233 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 19, 2022 Filed Oct 24, 2022 22:25 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 345 | $9.36 | $3,229.44 |
DisclosureSEC source: 0000899243-22-034057 · doc4.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,233 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 21:57 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-029043 · doc4.xml · nonDerivative · entry 1 Hagen Brett R · CIK 0001681782 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,578 F1 · shares: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on August 16, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.